Job Offers

Top 5 -yesterday

Top 5 -last week

Top 5 -last month

Partnership to bring Colombian pharmaceutical-grade cannabis to patients in Peru

Clever Leaves Holdings announced that its partner, Peruvian medicinal cannabis company Anden Naturals, has obtained the sanitary registration for the finished product, "Andenol 50," a 5% THC dominant oral solution produced by Clever Leaves in Colombia and sold under the Anden Naturals brand in Peru.  

Andenol 50 is Anden Naturals' first THC-dominant product to obtain sanitary registration for its commercialization as a finished product and is considered to be a "phytotherapeutic" product by the Peruvian health authority and indicating the passage of all quality inspections. Anden Naturals manufactures and markets medicinal cannabis products in Peru through magistral formulations as well as finished products imported from other countries. The company distributes medical cannabis products through its own pharmacies in the country.

Obtaining this sanitary registration of a THC-dominant finished product reflects both the unmatched quality of the medical cannabis cultivated by Clever Leaves and Clever Leaves' rigorous product development processes. 

"Our purpose at Clever Leaves is to produce the highest quality medical cannabis products for ourselves, our partners, and most importantly, for the millions of medical cannabis patients worldwide. The fact that Anden Naturals is the very first to obtain this sanitary registration in Peru is further proof that we are living up to our incredibly high standards and those of patients across the globe," said Andres Fajardo, CEO of Clever Leaves. "Due to the product's higher THC content, authorities are more demanding in granting the registration, and there is greater control over its use, prescription, and commercialization. We are proud to be the leader in setting the standard for every market in which we operate."

"With the addition of this high THC product, we can now offer a complete portfolio of products to our patients, offering the most robust and diversified portfolio in Peru. We are excited to have partnered up with Clever Leaves to produce Andenol 50, as we wanted to offer the highest possible quality to our patients. They have been a pleasure to work with, and we are extremely happy with the attention to detail they have shown throughout the registration process." 

The initial shipment of 1,000 units is set for Q1 of 2023, and the potential market is expected to be 30,000 registered patients, according to data as of August 2022.

For more information:
Clever Leaves      

Publication date:

Receive the daily newsletter in your email for free | Click here

Other news in this sector:

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber